Finanzen von Korsana Biosciences, Inc. (KRSA)KRSAKorsana Biosciences, Inc.

Evaluating the bottom line, Korsana Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -98.22%, provide a clear picture of how effectively KRSA converts its operational activities into shareholder value.

In the context of the broader market, KRSA competes directly with industry leaders such as TYRA and ANAB. With a market capitalization of $1.37B, it holds a significant position in the sector. When comparing efficiency, KRSA's gross margin of N/A stands against TYRA's N/A and ANAB's 100.00%. Such benchmarking helps identify whether Korsana Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Korsana's gross margin is currently at 100%, indicating potential for high profitability once revenue starts flowing. However, the company has been experiencing significant net income losses, with projections showing a loss of $3,177,000 in Q1 2026.